{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-104940","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2026-09-03T12:47:46+00:00","discovered_at":"2026-09-03T12:50:01.805599+00:00","generated_at":"2026-09-03T12:50:09.107165+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AbbVie completes $10.9B cash acquisition of Apogee Therapeutics","bullets":["Apogee shareholders received $135.11/share cash; total equity value ~$10.9B.","Adds zumilokibart (IL-13 mAb for atopic dermatitis) and APG273 (asthma candidate) to immunology pipeline.","Deal dilutive to adjusted EPS by $0.14 in 2026 and ~$0.46 in 2027; accretion expected from 2032.","AbbVie reaffirms FY2026 adjusted EPS guidance $13.87-$14.07 and Q3 guidance $3.84-$3.88."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-104940","json":"https://secwatch.observer/filing/0001104659-26-104940.json","markdown":"https://secwatch.observer/filing/0001104659-26-104940.md","text":"https://secwatch.observer/filing/0001104659-26-104940.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000110465926104940/0001104659-26-104940-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000110465926104940/tm2624674d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-03T12:50:09.107165+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}